...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gut and Liver >Serum Insulin-Like Growth Factor Binding Protein 7 for Esophagogastric Junction Adenocarcinoma Diagnosis
【24h】

Serum Insulin-Like Growth Factor Binding Protein 7 for Esophagogastric Junction Adenocarcinoma Diagnosis

机译：血清胰岛素样生长因子结合蛋白7用于食管胃癌腺癌腺癌诊断

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To the Editor: Liu et al . 1 published an article entitled “Serum insulin-like growth factor binding protein 7 as a potential biomarker in the diagnosis and prognosis of esophagogastric junction adenocarcinoma.” To evaluate the serum insulin-like growth factor binding protein 7 (IGFBP7) reflects for the diagnosis of esophagogastric junction adenocarcinoma (EJA), the investigators collected 120 EJA and 80 healthy controls. Serum IGFBP7 was determined using enzyme-linked immunosorbent assay. They found that serum IGFBP7 was significantly higher in EJA than healthy controls and the area under receiver operating characteristic curve is 0.794. Therefore, they concluded that serum IGFBP7 is used for EJA diagnosis. We applaud the authors’ attempt to find a noninvasive biomarker for EJA. However, we would like to raise some questions for the authors. First, when the author selected 80 healthy individuals as the healthy control, did the authors consider the problem of morbidity or source of the healthy control? However, the healthy control of this study should be insufficient, there will be a low-estimate of specificity and vice versa. 2 The healthy control of this study should be all non-cancers in the process of diagnosis and treatment came from the populations of the different standard exclusion. Second, this study consists of two independent cohorts from different population (healthy control and EJA), thus, this belongs to a typical two-gate design study. 2 Because of the controls and cases come from different individuals. From above questions for judging, these conclusions seem doubtful in this study. Obviously, this study design is a two-gate design study using healthy controls, and a two-gate design study with alternative diagnosis. In summary, the study provides a candidate biomarker about serum IGFBP7 for EJA diagnosis. However, they need a well-designed study for further verify the reliability of the conclusions. We recommend using a single-gate design study for diagnostic study.
机译：到编辑：刘等人。 1发布了一个标题为“血清胰岛素样生长因子结合蛋白7的文章，作为食管胃癌结腺癌诊断和预后的潜在生物标志物。”为了评价血清胰岛素样生长因子结合蛋白7（IGFBP7）反映了食管胃部结腺癌（EJA）的诊断，调查人员收集了120欧EJA和80个健康对照。使用酶联免疫吸附测定测定血清IGFBP7。他们发现，EJA的血清IGFBP7比健康对照显着高，并且接收器操作特性曲线下的面积为0.794。因此，他们得出结论，血清IGFBP7用于EJA诊断。我们赞扬作者试图为EJA找到一个非侵入性生物标志物。但是，我们想为作者提出一些问题。首先，当作者选择了80个健康的个人作为健康控制时，作者是否考虑了发病率或健康控制的来源的问题？然而，这项研究的健康控制应该不足，将有低估计的特异性，反之亦然。 2本研究的健康控制应该是诊断过程中的所有非癌症来自不同标准排除的群体。其次，本研究包括来自不同人口（健康控制和EJA）的两个独立队列，因此这属于典型的双栅设计研究。 2由于控制和案例来自不同的人。从上面的问题来看，这些结论在这项研究中似乎是值得怀疑的。显然，这项研究设计是一种使用健康控制的两门设计研究，以及具有替代诊断的双栅设计研究。总之，该研究为EJA诊断提供了关于血清IGFBP7的候选生物标志物。然而，他们需要精心设计的研究，以进一步验证结论的可靠性。我们建议使用单门设计研究进行诊断研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号